The area of drug discovery is experiencing a fast shift due to developments in the latest technologies, including artificial intelligence, precision medicine, and others.
To sort through vast amounts of molecular, biochemical, and genetic data drug developers focus more intently on machine learning.
With a compound annual growth rate of 15.3%, the worldwide drug discovery market increased from $85.42 billion in 2022 to $98.48 billion in 2023.
Enterprises retain an exclusive focus on incorporating the latest technologies to reduce the time for drug development.
Imaging technology makes it possible to visualize, characterize, and quantify non-invasive biological activity within organisms in response to drugs.
The year 2022 marked a return to some degree of normalcy for both the global economy and the pharmaceutical sector. However, we cannot say that it was a hassle-free phase. The Russia- Ukraine war has been quite destructive for the industry. The war had a direct impact on supply lines. Access to medicines was impacted heavily.
The year 2023 will be marked by changes in the existing scenario. More investments in technological incorporation are expected. The industry is experimenting with technology. Here is an attempt to summarize all the latest trends and some relevant solutions that are way ahead of others.
As a top-tier worldwide CRO for life science testing, the company offers researchers an industry-leading comprehensive suite of drug discovery tools to hasten the identification of potential therapeutic candidates. Through cutting-edge testing services and product resources, the company supports researchers in expediting the identification and development of candidate compounds by offering experience, depth, and breadth. This objective is made possible by a global team of committed scientists, information analysts, and client support specialists.
With commercial activities serving the Americas, Europe, Middle East, and Africa, as well as the Asia Pacific Region, Telix is an Australian company with its headquarters located in Melbourne. Significant operational flexibility, R&D capabilities, and support for commercial production requirements in Europe will be provided by the manufacturing center located in Belgium.
Axcelead is Japan’s first drug discovery solution provider, which began operations in 2017 by inheriting the drug discovery platform of Takeda Pharmaceutical Company Limited. As a partner of drug discovery players, the enterprise aims to create drug discovery innovation from Japan to the world by walking together with customers, thinking together.
Pharmidex is a contract research organization (CRO) that leverages its globally recognized experience in drug discovery, DMPK, ADMET/pharmacokinetics, and CNS/ oncology/respiratory to deliver translational solutions. Pharmidex was established in the UK in 2002 and is based in cutting-edge facilities in Hatfield and London. It offers professional advice and high-quality experimental data to aid in the discovery and development of new drugs.
Plex can discover potential targets based on chemical composition and associate patterns of gene expression with genetic or pharmacological modulators that produce similar profiles. Plex enables researchers to solve difficult drug development issues by identifying convergences across massive, disparate experimental data sets, such as big multi-omics and pharmacology data sets.
The development of new clinical candidates and the identification of novel targets are facilitated by Sapiensbio’s proprietary platform technology, Sapientia. The company expands its drug discovery solution based on data-driven technology.
The experts at Inotiv have extensive expertise in the industry and understand the significance of these fields to guide your molecule through the initial phases of drug development, known as foundational discovery. The enterprise provides a wide range of in vitro and in vivo research designs and implementation, encompassing cell and molecular biology, disease pharmacology, bioanalysis, DMPK, exploratory toxicology, and histopathology.
The world’s top provider of life science production and R&D technologies and services is GenScript Biotech Corporation (HK.1548). GenScript Biotech has four main platforms that are based on its reliable gene synthesis technology: the biologics contract development and manufacturing organization (CDMO) platform, the life science service and product platform, the integrated global cell therapy platform, and the industrial synthetic products platform.
Gene synthesis technology is GenScript Biotech’s reliable asset. It runs four main platforms: biologics contract development and manufacturing organization (CDMO) platform, life science service and product platform, integrated global cell therapy platform, and industrial synthetic products platform.
BioNTech is a multinational immunotherapy powerhouse that is completely integrated. The firm has been developing digital and automated processes and is constantly expanding its capacity for specialized production, whether it be for mass-market goods like COVID-19 vaccine or customized vaccinations